DGU 2011

Kongress der Deutschen Gesellschaft für Urologie (DGU)
German Society of Urology
63rd Annual Congress
September 14 - 17, 2011
Congress Center Hamburg, Germany

DGU 2011 - Impact of kidney function on the accuracy of urine-based tests for the diagnosis of urothelial cancer of the bladder - Session Highlights

HAMBURG, GERMANY (UroToday.com) - The authors investigated 449 consecutive patients with hematuria but without a history for urothelial cancer of the bladder.

DGU 2011 - Histologic subtypes of renal cell carcinoma demonstrate different activation of the mTOR pathway - Session Highlights

HAMBURG, GERMANY (UroToday.com) - With a tissue microarray, the expression of mTOR, phosphorylated mTOR (p-mTOR), and 4E binding protein in different tumor tissue samples were analyzed.

DGU 2011 - Treatment of patients with metastatic renal cell carcinoma: Reality in Germany - Session Highlights

HAMBURG, GERMANY (UroToday.com) - In a clinical database on patients with advanced or metastatic renal cell carcinoma (RCC), the first 622/1000 planned patients from > 100 centers were analyzed.

DGU 2011 - Intrinsic resistance to treatment with tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma - Session Highlights

HAMBURG, GERMANY (UroToday.com) - The authors looked at 35 patients with metastatic renal cell carcinoma showing primary resistance to the first tyrosine kinase inhibitor (TKI, 28 patients receiving sunitinib and 5 patients receiving sorafenib).

DGU 2011 - Nephron-sparing surgery in patients with renal tumors >7 cm: Functional and oncological outcome - Session Highlights

HAMBURG, GERMANY (UroToday.com) - The authors from two German academic centers analyzed their database with regard to elective nephron-sparing surgery for tumors > 7 cm.

DGU 2011 - Sorafenib (SOR) dosage patterns in > 4600 patients with renal cell carcinoma, including the elderly and patients treated for > 12 months: Results from an integrated database of 8 company-sponsored trials - Session Highlights

HAMBURG, GERMANY (UroToday.com) - The authors investigated 4,684 patients from 6 clinical trials and 2 expanded-access trials and analyzed the median dosage of sorafenib in all patients, elderly patients and patients having received sorafenib for > 12 months.

DGU 2011 - Phase-III trial to compare adjuvant versus progression-dependent chemotherapy of locally advanced urothelial cancer of the bladder following cystectomy: Gemcitabine monotherapy in patients not suitable for cisplatinum (AUO-trial AB 22/00) - Ses

HAMBURG, GERMANY (UroToday.com) - In this trial, 120 patients with locally advanced urothelial cancer of the bladder not suitable for cisplatinum-based chemotherapy were randomized to receive adjuvant monotherapy with gemcitabine (arm A) or progression-triggered gemcitabine (arm B).

DGU 2011 - Prospective, randomized, double-blind, multicenter phase-II trial comparing gemcitabine/cisplatinum +/- sorafenib in locally advanced or metastatic urothelial cancer of the bladder (AUO-trial AB 31/05) - Session Highlights

HAMBURG, GERMANY (UroToday.com) - In this trial, the addition of sorafenib (versus placebo) to first-line therapy with gemcitabine/cisplatinum (gem/cis) in patients with locally advanced or metastatic urothelial cancer of the bladder was tested.

DGU 2011 - Prospective long-term trial “UroScreen” for the early diagnosis of urothelial cancer of the bladder in a risk cohort of patient using urine-based tests - Session Highlights

HAMBURG, GERMANY (UroToday.com) - UroScreen is a prospective trial in 1,772 chemical workers who were exposed to aromatic amines in the past.

Log in

DGU 2011